2/29
09:10 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $32.50 price target on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $32.50 price target on the stock.
2/20
05:01 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY
2/14
08:03 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $32.50 price target on the stock, up previously from $25.00.
Medium
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $32.50 price target on the stock, up previously from $25.00.
2/14
07:15 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY
2/13
08:40 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at BTIG Research.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at BTIG Research.
2/13
08:14 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY
2/13
08:03 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $32.50 price target on the stock, up previously from $29.00.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $32.50 price target on the stock, up previously from $29.00.
2/13
08:03 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $32.50 price target on the stock, up previously from $29.00.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $32.50 price target on the stock, up previously from $29.00.
2/13
08:03 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $32.50 price target on the stock.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $32.50 price target on the stock.
2/13
08:03 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
2/13
07:07 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
2/13
07:07 am
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
2/13
05:54 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY
2/13
05:54 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY
2/13
05:50 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY
2/12
12:17 pm
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at William Blair.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at William Blair.
2/12
12:17 pm
cbay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at William Blair.
Low
Report
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "market perform" rating re-affirmed by analysts at William Blair.
2/12
11:42 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY
2/12
11:42 am
cbay
Rating for CBAY
Low
Report
Rating for CBAY